ENTITY

Abivax (ABVX FP)

2
Analysis
Health Care • France
Abivax is a clinical-stage biotechnology company. The Company focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax operates in France.
more
bullish•Abivax
•29 Sep 2026 13:57

Primer: Abivax (ABVX FP) - Sep 2026

Abivax (ABVX FP) has achieved a pivotal clinical inflection with the successful completion of its global Phase 3 ABTECT program evaluating lead...

Share
bullish•Abivax
•01 Jul 2026 13:14

Abivax (ABVX FP): Synthetic Expert Call Transcript (01 Jul 2026)

Obefazimod’s efficacy delta of ~40% is highly competitive with AbbVie’s Rinvoq, but its safety-adjusted positioning hinges entirely on avoiding a...

Share
x